Camurus shares fall 7% after FDA rejects acromegaly drug
Investing.com Gold reports: Camurus shares fall 7% after FDA rejects acromegaly drug. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Camurus shares fall 7% after FDA rejects acromegaly drug. Full body text was unavailable at ingest time, so this brief is based on headline context.